Strengthening Advanced Therapies´ Manufacturing Through Cost-Effectiveness and Quality

VIVEbiotech has released a new video featuring Maider Goyena, Chief Financial Officer, who shares insights into how financial strategy and resource optimization play a crucial role in the manufacturing of advanced therapies.

As the cell and gene therapy sector continues to expand, developers increasingly seek CDMOs capable of providing GMP manufacturing solutions that are not only scientifically robust but also economically sustainable. This balance between cost-effectiveness and quality has become a key factor in accelerating programs from early development toward clinical success.

At VIVEbiotech, budget planning and resource allocation are managed with rigor to ensure that every investment made by clients generates measurable value throughout their projects. One example of this commitment is the company’s integrated offer model, which consolidates all essential services into a single, comprehensive proposal. This approach streamlines decision‑making, reduces operational complexity, and ensures efficiency from the outset of each collaboration.

Beyond financial strategy, VIVEbiotech positions itself as a global partner for therapy developers—supporting both scientific and economic progress. The company is proud to contribute to the advancement of innovative treatments that have the potential to make a meaningful difference in patients’ lives.

You can watch the full video here.